On Sept. 29, 2020, the National Institute of Allergy and Infectious Diseases announced that a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection had shown that the vaccine was well-tolerated and generated a strong immune response in older adults.

The report, published in the New England Journal of Medicine described the findings from the study.